The stock has a 36-month beta value of 0.99. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LRMR is 37.27M, and at present, short sellers hold a 8.92% of that float. On October 03, 2024, the average trading volume of LRMR was 521.13K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LRMR) stock’s latest price update
Larimar Therapeutics Inc (NASDAQ: LRMR) has seen a rise in its stock price by 0.32 in relation to its previous close of 6.27. However, the company has experienced a -0.79% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-19 that BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the annual International Congress for Ataxia Research (ICAR) being held November 12-15, 2024 in London, U.K. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia by delivering frataxin to mitochondria.
LRMR’s Market Performance
LRMR’s stock has fallen by -0.79% in the past week, with a monthly drop of -9.10% and a quarterly drop of -17.56%. The volatility ratio for the week is 4.99% while the volatility levels for the last 30 days are 10.04% for Larimar Therapeutics Inc The simple moving average for the past 20 days is -11.15% for LRMR’s stock, with a -17.53% simple moving average for the past 200 days.
Analysts’ Opinion of LRMR
Robert W. Baird, on the other hand, stated in their research note that they expect to see LRMR reach a price target of $16. The rating they have provided for LRMR stocks is “Outperform” according to the report published on September 04th, 2024.
Leerink Partners gave a rating of “Outperform” to LRMR, setting the target price at $25 in the report published on April 03rd of the current year.
LRMR Trading at -17.99% from the 50-Day Moving Average
After a stumble in the market that brought LRMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.02% of loss for the given period.
Volatility was left at 10.04%, however, over the last 30 days, the volatility rate increased by 4.99%, as shares sank -19.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.26% lower at present.
During the last 5 trading sessions, LRMR fell by -0.79%, which changed the moving average for the period of 200-days by +48.70% in comparison to the 20-day moving average, which settled at $7.01. In addition, Larimar Therapeutics Inc saw 38.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LRMR starting from Hamilton Thomas Edward, who purchase 57,208 shares at the price of $8.74 back on Feb 16 ’24. After this action, Hamilton Thomas Edward now owns 564,798 shares of Larimar Therapeutics Inc, valued at $499,998 using the latest closing price.
Flynn James E, the Director of Larimar Therapeutics Inc, purchase 4,290,617 shares at $8.74 during a trade that took place back on Feb 16 ’24, which means that Flynn James E is holding 6,151,406 shares at $37,499,993 based on the most recent closing price.
Stock Fundamentals for LRMR
The total capital return value is set at -0.3. Equity return is now at value -37.48, with -33.44 for asset returns.
Based on Larimar Therapeutics Inc (LRMR), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.68.
Currently, EBITDA for the company is -41.45 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.93.
Conclusion
To sum up, Larimar Therapeutics Inc (LRMR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
